Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MED
MED logo

MED Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
13.180
Open
13.150
VWAP
12.72
Vol
456.70K
Mkt Cap
139.32M
Low
12.460
Amount
5.81M
EV/EBITDA(TTM)
--
Total Shares
11.12M
EV
-29.62M
EV/OCF(TTM)
-7.97
P/S(TTM)
0.40
Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.
Show More

Events Timeline

(ET)
2026-05-26
16:10:00
Medifast Appoints Nicholas Johnson as CEO
select
2026-05-04 (ET)
2026-05-04
16:20:00
Sees Q2 Revenue of $60M-$80M, Estimate at $74.7M
select
2026-05-04
16:20:00
Sees FY26 Revenue of $270M to $300M
select
2026-05-04
16:10:00
Medifast Q1 Revenue of $76.0M Beats Estimates
select
2026-03-20 (ET)
2026-03-20
08:40:00
Medifast Nominates Independent Director Candidates
select
2026-02-17 (ET)
2026-02-17
16:21:00
Sees FY26 Revenue of $270M-$300M
select
2026-02-17
16:10:00
Sees Q1 Revenue of $65M to $80M
select
2026-02-17
16:10:00
Medifast Q4 Revenue $75.1M, Down from $119.003M Last Year
select

News

seekingalpha
2.0
05-26seekingalpha
Major U.S. Indices Mixed as Zscaler Shares Decline Amid Guidance Concerns
  • Market Performance: On Tuesday, major Wall Street indices finished mixed as investors assessed the potential for a resolution in the U.S.-Iran conflict, with the blue-chip Dow down 0.2%, the S&P 500 up 0.6%, and the tech-heavy Nasdaq Composite leading with a 1.2% gain.
  • Zscaler Earnings: Zscaler's shares fell in after-hours trading despite reporting better-than-expected third-quarter results, with an adjusted EPS of $1.08 and revenue rising 25% year-over-year to $850.5 million; however, mixed guidance overshadowed these results, leading to investor disappointment.
  • Medifast Leadership Change: Medifast appointed Nicholas Johnson as CEO effective June 1, 2026, succeeding Dan Chard, who will remain as chairman of the board; this leadership transition could impact the company's strategic direction and market performance moving forward.
  • Firefly Aerospace Contract: Firefly Aerospace was awarded a $75 million subcontract from NASA's Jet Propulsion Laboratory to deliver four drones for NASA's MoonFall mission, although shares fell about 5% at the time of the announcement, this contract could support future business growth for the company.
seekingalpha
5.0
05-26seekingalpha
Medifast Appoints New CEO Nicholas Johnson Effective June 2026
  • Executive Change: Medifast has appointed Nicholas Johnson as CEO effective June 1, 2026, succeeding current CEO Dan Chard, who will remain as chairman of the board, ensuring continuity and stability in corporate governance.
  • Strategic Revenue Outlook: The company reaffirms its revenue outlook for 2026 at $270 million to $300 million, indicating growth potential in the coming years, particularly with profitability improvement plans set to begin in Q4 2026 aimed at enhancing overall financial performance.
  • Cost Reduction Initiative: Medifast is implementing a $30 million cost-cutting plan designed to optimize operational efficiency and enhance profitability, a move that will help the company maintain its competitive edge in a challenging market.
  • Positive Market Reaction: Despite weak Q1 performance, Medifast's stock has surged, reflecting investor confidence in the company's future strategy and leadership changes, which may attract more investor interest.
Newsfilter
8.5
05-15Newsfilter
OPTAVIA Sets New Standards in Weight Loss Industry
  • Market Size: The global weight loss industry is projected to reach $16.3 billion by 2025, yet the uneven peer-reviewed clinical validation across programs highlights a critical need for scientific backing in the sector.
  • Clinical Research Support: OPTAVIA's clinical approach is backed by 18 randomized controlled trials and over 30 scientific studies, ensuring the effectiveness and scientific credibility of its weight loss programs, thereby enhancing trust among consumers and healthcare professionals.
  • Importance of Coaching Support: Research indicates that clients using the OPTAVIA program with coaching support lose an average of 10 times more weight and 17 times more fat than those without, underscoring the crucial role of personalized guidance in the weight loss journey.
  • Focus on Metabolic Health: As the market floods with weight loss solutions, OPTAVIA emphasizes the importance of metabolic health through scientific research, shifting the industry's focus from mere weight loss to body composition and long-term health management.
seekingalpha
9.5
05-05seekingalpha
Medifast Q1 Earnings Beat Expectations, Shares Surge 18%
  • Significant Stock Surge: Medifast shares jumped nearly 18% on Tuesday, rising from $10.63 to approximately $12.63, significantly outperforming the S&P 500's 15.13% one-day gain, reflecting market optimism about the company's future potential.
  • Weak Financial Performance: Despite Q1 revenue falling 34.3% year-over-year to $76 million, primarily due to a 44.9% drop in active coaches to 14,000, the average revenue per active coach increased by 19.2% to $5,432, indicating improved productivity among the remaining coaches.
  • Effective Cost Control: The company's gross profit declined 38.6% to $51.8 million in Q1, yet SG&A expenses fell by 35.6%, demonstrating the effectiveness of its cost-cutting measures, with expectations of generating over $30 million in future savings.
  • Positive Future Outlook: Although the net loss widened to $2.1 million (or $0.19 per share), the company ended the quarter with $168.9 million in cash and no debt, with management stating that they have realigned their cost structure effectively and plan to launch a new metabolic health system in July, which could further fuel stock price increases.
seekingalpha
9.5
05-04seekingalpha
Medifast Q1 2026 Earnings Call Insights and Outlook
  • Initial Revenue Growth: Medifast reported Q1 2026 revenue of $76 million, a 34.3% year-over-year decline, yet marked the first sequential revenue growth in three years, indicating early signs of business stabilization that could lay the groundwork for future market recovery.
  • Declining Coach Numbers: The number of active earning coaches fell to approximately 14,000, down 44.9% year-over-year; however, the average revenue per coach increased by 19.2% to $5,432, suggesting progress in enhancing coach productivity despite the overall decline.
  • Cost Structure Optimization: The company anticipates generating over $30 million in future savings through a realignment of its cost structure, which not only helps address market realities but may also facilitate a return to profitability starting in Q4 2026, thereby strengthening financial health.
  • New Product Line Launch: Medifast plans to unveil a new comprehensive metabolic system at its coach convention in July, with management reiterating that this product launch will be crucial for restoring profitability, expected to drive sustained earnings growth into 2027 and beyond.
seekingalpha
9.5
05-03seekingalpha
Medifast (MED) to Announce Q1 Earnings on May 4th
  • Earnings Announcement Schedule: Medifast (MED) is set to release its Q1 2023 earnings report on May 4th after market close, with consensus EPS estimate at -$0.52 and revenue estimate at $69.2 million, reflecting a 40.2% year-over-year decline.
  • Historical Performance: Over the past two years, Medifast has exceeded EPS estimates 88% of the time and revenue estimates 88% of the time, indicating a degree of stability in its financial performance despite current challenges.
  • Expectation Adjustments: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and one downward revision, suggesting market caution regarding future performance.
  • Future Revenue Targets: Medifast has outlined a revenue target of $270 million to $300 million for 2026, indicating the company's commitment to driving execution amid CEO transition and a focus on metabolic health for long-term growth.

Valuation Metrics

The current forward P/E ratio for Medifast Inc (MED.N) is 12.48, compared to its 5-year average forward P/E of 10.61. For a more detailed relative valuation and DCF analysis to assess Medifast Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
10.61
Current PE
12.48
Overvalued PE
76.57
Undervalued PE
-55.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
5.81
Current EV/EBITDA
-22.63
Overvalued EV/EBITDA
10.77
Undervalued EV/EBITDA
0.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.83
Current PS
0.57
Overvalued PS
1.30
Undervalued PS
0.37

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

surging stocks between 10 to $20
Intellectia · 547 candidates
Price: $10.00 - $20.00Moving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
FSEA logo
FSEA
First Seacoast Bancorp Inc
78.21M
VRDN logo
VRDN
Viridian Therapeutics Inc
1.93B
BDSX logo
BDSX
Biodesix Inc
151.02M
AIOS logo
AIOS
AIOS Tech Inc
63.69M
ONEG logo
ONEG
OneConstruction Group Ltd
175.36M
IART logo
IART
Integra Lifesciences Holdings Corp
1.03B
rerun right now to see if the list changes
Intellectia · 29 candidates
Price: $3.00 - $100.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 60One Day Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SIDU logo
SIDU
Sidus Space Inc
234.80M
DBGI logo
DBGI
Digital Brands Group Inc (Pre-Reincorporation)
68.45M
MED logo
MED
Medifast Inc
128.60M
AAP logo
AAP
Advance Auto Parts Inc
2.75B
CMBT logo
CMBT
CMB.TECH NV
3.30B
LSTA logo
LSTA
Lisata Therapeutics Inc
35.81M

Whales Holding MED

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Medifast Inc (MED) stock price today?

The current price of MED is 12.53 USD — it has decreased -4.71

What is Medifast Inc (MED)'s business?

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.

What is the price predicton of MED Stock?

Wall Street analysts forecast MED stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MED is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Medifast Inc (MED)'s revenue for the last quarter?

Medifast Inc revenue for the last quarter amounts to 76.04M USD, decreased -34.29

What is Medifast Inc (MED)'s earnings per share (EPS) for the last quarter?

Medifast Inc. EPS for the last quarter amounts to -0.19 USD, increased 171.43

How many employees does Medifast Inc (MED). have?

Medifast Inc (MED) has 380 emplpoyees as of June 01 2026.

What is Medifast Inc (MED) market cap?

Today MED has the market capitalization of 139.32M USD.